WO2004071419A3 - Methods and compositions for modulating glutamate transport activity in the nervous system - Google Patents
Methods and compositions for modulating glutamate transport activity in the nervous system Download PDFInfo
- Publication number
- WO2004071419A3 WO2004071419A3 PCT/US2004/003228 US2004003228W WO2004071419A3 WO 2004071419 A3 WO2004071419 A3 WO 2004071419A3 US 2004003228 W US2004003228 W US 2004003228W WO 2004071419 A3 WO2004071419 A3 WO 2004071419A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- transport activity
- nervous system
- glutamate transport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002488143A CA2488143A1 (en) | 2003-02-07 | 2004-02-05 | Methods and compositions for modulating glutamate transport activity in the nervous system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44606203P | 2003-02-07 | 2003-02-07 | |
US60/446,062 | 2003-02-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004071419A2 WO2004071419A2 (en) | 2004-08-26 |
WO2004071419A3 true WO2004071419A3 (en) | 2006-06-22 |
Family
ID=32869450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/003228 WO2004071419A2 (en) | 2003-02-07 | 2004-02-05 | Methods and compositions for modulating glutamate transport activity in the nervous system |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2488143A1 (en) |
WO (1) | WO2004071419A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100679306B1 (en) * | 2005-03-31 | 2007-02-06 | 아미코젠주식회사 | Pharmaceutical composition for treating or preventing a neurological brain disease comprising lignan compounds |
RU2406499C2 (en) | 2005-05-17 | 2010-12-20 | Сантен Фармасьютикал Ко., Лтд. | Preventive or therapeutic agent for treatment of keratoconjuctival disorders |
GB0721616D0 (en) * | 2007-11-02 | 2007-12-12 | Queen Mary & Westfield College | Treatment of spinal cord injury |
KR20100124756A (en) | 2008-02-28 | 2010-11-29 | 산텐 세이야꾸 가부시키가이샤 | Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder |
WO2014076702A1 (en) * | 2012-11-14 | 2014-05-22 | Ramot At Tel-Aviv University Ltd. | Combination treatment for amyotrophic lateral sclerosis (als) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020098473A1 (en) * | 2000-07-25 | 2002-07-25 | Edwards Robert H. | Novel glutamate transporters |
US20030050224A1 (en) * | 2001-08-20 | 2003-03-13 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
US6808893B1 (en) * | 1999-10-23 | 2004-10-26 | The Johns Hopkins University School Of Medicine | Glutamate transporter associated proteins and methods of use thereof |
-
2004
- 2004-02-05 WO PCT/US2004/003228 patent/WO2004071419A2/en active Application Filing
- 2004-02-05 CA CA002488143A patent/CA2488143A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6808893B1 (en) * | 1999-10-23 | 2004-10-26 | The Johns Hopkins University School Of Medicine | Glutamate transporter associated proteins and methods of use thereof |
US20020098473A1 (en) * | 2000-07-25 | 2002-07-25 | Edwards Robert H. | Novel glutamate transporters |
US20030050224A1 (en) * | 2001-08-20 | 2003-03-13 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
CA2488143A1 (en) | 2004-08-26 |
WO2004071419A2 (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1471909A4 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
WO2006044825A3 (en) | Mitotic kinesin inhibitors and methods of use thereof | |
WO2004039774A3 (en) | Mitotic kinesin inhibitors | |
WO2003099211A3 (en) | Mitotic kinesin inhibitors | |
WO2003049678A3 (en) | Mitotic kinesin inhibitors | |
WO2003050064A3 (en) | Mitotic kinesin inhibitors | |
WO2003049527A3 (en) | Mitotic kinesin inhibitors | |
WO2003049679A3 (en) | Mitotic kinesin inhibitors | |
WO2003050122A3 (en) | Mitotic kinesin inhibitors | |
WO2004108133A3 (en) | Modulators of vr1 receptor | |
WO2006047516A3 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
WO2004058148A3 (en) | Mitotic kinesin inhibitors | |
WO2004058700A3 (en) | Mitotic kinesin inhibitors | |
WO2007047447A3 (en) | Diuretic-like compound analogs useful for regulation of central nervous system disorders | |
WO2006055871A3 (en) | Treatment for multiple sclerosis | |
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
WO2005065183A3 (en) | Mitotic kinesin inhibitors | |
IL186707A (en) | Mitotic kinesin inhibitors and pharmaceutical compostions comprising them | |
EP1802321A4 (en) | Compositions and methods for modulating pgc-1-alpha to treat neurological diseases and disorders | |
AU2003272728A1 (en) | Methods and compositions for treatment of neurological disorder | |
WO2004071419A3 (en) | Methods and compositions for modulating glutamate transport activity in the nervous system | |
AU2003259246A1 (en) | Methods for the use of neurotoxin in the treatment of urologic disorders | |
WO2006011136A3 (en) | Novel naphthoquinone derivatives and uses thereof | |
WO2005060654A3 (en) | Mitotic kinesin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2488143 Country of ref document: CA |
|
122 | Ep: pct application non-entry in european phase |